GlassScriptPhysician profile
Anne Luu
NPI 1437634045
$8,354.92
in general payments reported to CMS, 2019-2025
36 companies · $558 in 2025
The $558 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,508 · 2022: $1,574 · 2023: $1,402 · 2024: $2,314 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,273.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,678.80 | 2021-2025 | Farxiga, Breztri, Fasenra |
| Amgen INC. | $1,461.86 | 2021-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $557.99 | 2021-2024 | Jardiance |
| Abbvie INC. | $505.48 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $479.55 | 2021-2025 | |
| Novo Nordisk INC | $468.31 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $361.77 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $317.83 | 2021-2022 | |
| Glaxosmithkline, LLC. | $267.76 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Ironwood Pharmaceuticals, INC | $256.25 | 2021-2024 | Linzess |
| Ardelyx, INC. | $233.77 | 2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $180.62 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $176.92 | 2021-2025 | Zoryve |
| Lilly USA, LLC | $173.61 | 2021-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $170.35 | 2022-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $168.53 | 2021-2022 | |
| Esperion Therapeutics, INC. | $111.90 | 2021 | |
| Almatica Pharma LLC | $103.07 | 2023-2024 | Loreev Xr, Teriparatide |
| E.R. Squibb & Sons, L.L.C. | $89.50 | 2021-2024 | Eliquis |
| Dexcom, INC. | $80.90 | 2022-2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $71.71 | 2024 | Rexulti |
| Scilex Pharmaceuticals INC. | $61.09 | 2021-2024 | Ztlido |
| Radius Health, INC. | $53.75 | 2021 | |
| Biogen, INC. | $43.13 | 2021 | |
| Janssen Pharmaceuticals, INC | $41.45 | 2022 | |
| Hikma Pharmaceuticals USA | $34.87 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $27.68 | 2025 | Gemtesa |
| Gilead Sciences, INC. | $24.91 | 2023 | |
| Corium, LLC | $24.89 | 2023 | Adlarity |
| Nestle Healthcare Nutrition INC. | $22.22 | 2021 | |
| Vivus LLC | $20.80 | 2022 | |
| Genentech USA, INC. | $19.05 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.79 | 2024 | Xifaxan |
| Pfizer INC. | $17.67 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.13 | 2024 | Quviviq |
| Eyevance Pharmaceuticals LLC | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.